Kalydeco (ivacaftor) is applied as a targeted therapy for cystic fibrosis ( CF) in patients aged 1 month and older who carry a specific CFTR gene mutation that is responsive to the treatment. It may be part of symptomatic management by contributing to easing the overall symptom load over the long term.

---

The medication is primarily used to address the core functional issue in CF caused by CFTR gating mutations (e.g., G551D, R117H) and other responsive genetic defects. This therapeutic approach is commonly used to help with persistent respiratory symptoms, including chronic cough and sputum production, alongside systemic manifestations like issues with nutritional status and weight gain. Furthermore, it is applied across domains where additional symptomatic support is needed to help with managing the frequency of acute, serious pulmonary exacerbations.

“This treatment supports the patient during difficult episodes by easing discomfort and assists with maintaining functional stability.”

Quick Fact: Relief for Pulmonary and Nutritional Symptoms

The benefit of this therapy may assist with maintaining functional stability through contributing to better lung function ( FEV1) and contributes to healthier Body Mass Index ( BMI) trajectories, supporting general well-being during symptomatic phases.

Eligibility Scope for Kalydeco (Oral)

Kalydeco is strictly indicated for the treatment of Cystic Fibrosis ( CF) in patients who have at least one specific CFTR gene mutation that is responsive to ivacaftor potentiation, as verified by an appropriate mutation test. The medicine is not effective and not recommended for monotherapy in patients who are homozygous for the F508del mutation.

Classification	Population or Condition	Status
Age Restriction	Infants under 1 month of age	Not Recommended (Safety/efficacy not established)
Genotype Exclusion	Patients homozygous for F508del	Not Effective/Not Recommended
Hypersensitivity	Known reaction to ivacaftor or excipients	Contraindicated

Conditional Use and Limitations

Use is established for patients 1 month of age and older. Those with moderate hepatic impairment (Child-Pugh Class B) are conditionally eligible and require an officially specified dose reduction. For severe hepatic impairment (Child-Pugh Class C), use is generally not recommended unless the prescribing physician determines the benefits clearly outweigh the risks. Severe renal impairment requires caution due to limited data.

Eligibility during pregnancy and lactation is not a standard approval but must be determined by a healthcare provider based on a mandatory individual risk-benefit assessment. In pediatric patients, baseline and follow-up ophthalmological examinations are required.

The interaction profile of Kalydeco (ivacaftor) is primarily defined by its high sensitivity as a substrate of the CYP3A enzyme system and its documented potential as a weak inhibitor of both CYP3A and the transporter P-glycoprotein (P-gp).

Contraindicated and Restricted Combinations

Co-administration with strong CYP3A inducers is formally not recommended by regulatory authorities. These include specific medicines such as rifampin, phenobarbital, carbamazepine, and the herbal product St. John’s Wort, as they substantially decrease ivacaftor exposure and may diminish effectiveness.

Interaction Classification	Interacting Agents (Examples)
Avoidance Required (Strong CYP3A Inducers)	Rifampin, Carbamazepine, St. John's Wort
Avoidance Required (Food/Juice)	Grapefruit, Seville Oranges

Interactions Modifying Exposure

Co-administration with strong or moderate CYP3A inhibitors significantly increases ivacaftor exposure (e.g., ketoconazole increased AUC by 8.5-fold). Regulatory labels thus require a reduction in the administration frequency of Kalydeco when taken with strong inhibitors (e.g., ketoconazole, itraconazole) or moderate inhibitors (e.g., fluconazole, erythromycin).

Ivacaftor and its main metabolite (M1) are also weak inhibitors of P-gp, which may increase the systemic exposure of sensitive P-gp substrates, such as digoxin. Caution and monitoring of the co-administered drug are recommended for P-gp or CYP2C9 substrates with narrow therapeutic indices. Ivacaftor must be administered with fat-containing food to achieve adequate systemic exposure.

Kalydeco (ivacaftor) is a Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) potentiator, an agent that binds to and modulates the function of the defective protein. Its action is exerted directly on the CFTR protein at the epithelial cell surface.

---

CFTR Channel Gating Modulation

This mechanism involves the agent binding to the CFTR protein, resulting in an increase in the probability of channel opening (gating). This applies to CFTR proteins that are correctly localized to the cell membrane but exhibit reduced channel-open probability or conductance.

---

Ion and Water Transport Modulation

By stabilizing the open state of the CFTR chloride channel, the drug initiates a signaling sequence that drives an elevation in the trans-membrane flux of chloride ions and secondary movement of water across the epithelial cell membranes. This pathway adjustment modulates the transepithelial ion transport in relevant organ systems.

---

Alteration of Fluid Secretion Characteristics

The resulting physiological consequence of increased channel-open probability is a change in the hydration of various luminal secretions. This action alters the biophysical properties, including the composition and consistency, of these fluids in affected organs.

How to Use Kalydeco (Ivacaftor) Oral: Official Administration Guidelines

Kalydeco (ivacaftor) is administered orally and must be used according to specific instructions to ensure proper absorption and effectiveness.

---

Standard Dosing and Frequency

Patient Group	Dosage Form & Strength	Frequency
Adults and Pediatric Patients ge 6 Years	150 mg tablet	Every 12 hours
Pediatric Patients 1 Month to <6 Years	Weight-based oral granules (e.g., 5.8 mg, 75 mg packets)	Every 12 hours

---

Administration Conditions and Preparation

Must-Take-With-Fat Rule: All doses of Kalydeco must be taken with fat-containing food to enhance the absorption of the medication. Examples include eggs, cheese, butter, or whole-milk products.

Preparation Steps:

1. Tablets must be swallowed whole. They should not be chewed, crushed, or dissolved.
2. Oral Granules must be mixed with one teaspoon (5 mL) of soft food or liquid (e.g., yogurt, puréed fruit, or milk) that is at or below room temperature. The entire mixture must be consumed completely within one hour of preparation.

Missed Dose Procedure:

• If less than 6 hours have passed since the scheduled dose, the dose should be taken immediately with a fat-containing food.
• If more than 6 hours have passed, the missed dose should be skipped, and the next dose should be taken at the regularly scheduled time.
• Never take two doses at the same time to make up for a missed dose.

---

Population and Concomitant Use Adjustments

Specific dosage reductions are mandated for patients with moderate or severe hepatic impairment (Child-Pugh Class B or C) and for patients taking strong or moderate CYP3A inhibitors, such as certain antifungal or antibiotic medications. Additionally, the use of foods or drinks containing grapefruit or Seville oranges must be avoided while on treatment.

Research evidence / Overview of studies for Kalydeco (Oral)

---

Evidence for Core CFTR Gating Mutations (e.g., G551D)

Research into Kalydeco was studied for patients who have specific CFTR gene changes, such as the G551D mutation. These initial investigations primarily used short-term (randomized, placebo-controlled trials ( RCTs)). This study design helps researchers observe patterns by comparing outcomes for a study group to a non-active substitute (placebo) under controlled conditions.

The main focus of these RCTs was to measure changes in lung function, specifically the forced expiratory volume in 1 second ( FEV1), and other outcomes related to systemic or functional imbalance, such as body weight and the frequency of pulmonary exacerbations. Across the various age groups studied, findings described patterns in the measured outcomes, including measured changes in Sweat Chloride concentration, a key biomarker monitored in cystic fibrosis studies. Research findings describe group patterns, not outcomes for an individual.

Evidence for Other CFTR Responsive Mutations

Following the initial research, studies explored the use of Kalydeco in people with other less common CFTR mutations, such as R117H. Evidence is often derived from smaller clinical trials or studies where multiple mutations are grouped together for analysis. Research examined many of the same outcomes reflecting daily functioning or activity level as the core trials. The findings indicated patterns of change in these measured outcomes, though the reported changes often varied by specific mutation studied. Because the sample sizes were modest for some of these individual mutation groups, evidence quality varies across studies, and subgroup findings are uncertain.

---

Long-Term Studies and Sustained Patterns

To observe how the measured changes persist over time, research has explored longer-term patterns through open-label extension studies and longitudinal observational studies using patient registry data. These longer-term research contexts involved monitoring physiological strain or stress and functional measures over multiple years. For outcomes like overall survival or organ-transplantation rates—which take many years to observe—research uses mainly non-randomized registry data that compare treated and untreated patients. These observational findings describe patterns in the study populations, but comparative evidence is lacking from controlled, long-term trials.

Common questions about Kalydeco (Oral) (FAQ)

---

Q: How does Kalydeco differ from other oral treatments for this condition?

According to official product information, Kalydeco is indicated as a monotherapy, meaning it is a single-ingredient drug (ivacaftor) used alone for certain genetic mutations. Other oral treatments for this condition may contain ivacaftor combined with one or more additional active substances.

---

Q: Do people have to take Kalydeco forever, or is it a short-term treatment?

Regulatory information indicates that clinical trials and long-term registry studies assessing the benefits of Kalydeco have followed patients over periods of up to several years. While these studies show the medicine is used over the long term, the official label does not specify a maximum duration for how long the therapy must be taken.

---

Q: Does Kalydeco interact with common over-the-counter pain relievers?

Kalydeco is known to interact with the CYP3A enzyme system, which can affect how other medicines are processed in the body. Regulatory sources generally emphasize that patients should discuss all medicines they take, including common over-the-counter (OTC) products and pain relievers, with their healthcare provider.

---

Q: Are there any specific vitamins or supplements that are known to interact with Kalydeco?

Official sources state that the herbal product St. John’s Wort is a strong CYP3A inducer and is formally not recommended for use with Kalydeco. Patients are generally advised in official documents to discuss all supplements with their healthcare provider to ensure safety.

---

Q: Can alcohol consumption affect how Kalydeco works in the body?

Dizziness is a listed side effect of Kalydeco. While official drug labels often do not contain specific warnings about alcohol, a healthcare professional can determine if there are any individual risks related to alcohol use and side effects like dizziness.

---

Q: What are the general safety concerns for Kalydeco in older adults?

The overall safety information for Kalydeco is based on studies that included adult patients. Specific dosage adjustment is generally not required based solely on age, but adjustments are mandatory for patients with pre-existing hepatic (liver) or renal (kidney) impairment, such as hepatic or renal impairment, which are factors that must be considered when determining dosing.

---

Q: How quickly do people generally notice the effects of Kalydeco?

Official research evidence indicates that improvements in lung function, measured by FEV1, were observable as early as four weeks into the pivotal clinical trials. Longer-term observational studies have also noted patterns of sustained benefits starting within the initial weeks of treatment.

---

Q: Are there different brand names for the medicine ivacaftor besides Kalydeco?

The active ingredient in Kalydeco is ivacaftor. While Kalydeco is the brand name for ivacaftor monotherapy, ivacaftor is also included as a key component in other combination modulator therapies that are approved by regulatory agencies.

---

Q: Can Kalydeco interact with birth control pills?

Regulatory studies assessing combination therapies that include ivacaftor suggest that the drug is not expected to modify the efficacy of oral hormonal contraceptives. As with any medicine, a patient's use of birth control pills should be discussed with a healthcare provider.

---

Q: Do people ever develop a tolerance to Kalydeco over time?

Long-term observational studies, some tracking patients for up to four years, indicate that improvements in lung function and other clinical benefits were maintained across the entire study period. This evidence suggests the benefits measured in studies were sustained over the time period assessed.

---

Q: Does Kalydeco have an effect on kidney function?

Kalydeco is primarily processed by the liver, but the official label includes a caution for use in patients with severe renal impairment (kidney disease) or end-stage renal disease. This caution is based on limited available data in this specific population.

---

Q: Is Kalydeco known to affect a person's blood pressure?

Yes, increased blood pressure is a documented adverse drug reaction listed in official product information. Official sources note that monitoring of blood pressure is a standard recommendation, particularly for individuals with existing hypertension (high blood pressure).

---

Q: Can Kalydeco be taken alongside common antibiotics?

Co-administration with certain antibiotics that act as strong or moderate CYP3A inhibitors (like ketoconazole or erythromycin) requires a Kalydeco dose reduction. For antibiotics outside of these groups, a healthcare professional can determine if a review is needed to check for potential drug-drug interactions.

---

Q: Do people feel more tired or energized when starting Kalydeco?

According to the official safety profile, fatigue (feeling tired) is listed as a common adverse reaction that was observed in clinical trials. This means that fatigue occurred in at least 1 out of 100 patients studied.

---

Q: What distinguishes Kalydeco from combination modulator therapies?

Kalydeco is classified as a single-active-ingredient product (ivacaftor) that functions solely as a CFTR potentiator (gating corrector). Combination therapies include ivacaftor plus additional active CFTR modulators that target other aspects of the defective protein, such as its processing or trafficking.

---

Q: What is the most important piece of safety information a patient should know about Kalydeco?

The safety information in regulatory documents includes the requirement for mandatory liver function monitoring before and during treatment. Other key points include the risk of cataracts in children and the requirement to avoid strong CYP3A inducers and certain fruit juices like grapefruit.

---

Q: What is the typical timeline for seeing maximum benefit from Kalydeco?

The maximum effect on lung function was generally assessed over the 24-week duration of the pivotal clinical trials. These studies indicated that the benefits were sustained over the full duration, and they continued to be maintained in subsequent longer-term studies.

---

Q: What is the difference between Kalydeco and other ivacaftor-containing medicines?

Kalydeco is officially recognized as a monotherapy, meaning it contains only the active ingredient ivacaftor. Other ivacaftor-containing products are regulatory-approved combination treatments that include additional active CFTR modulator ingredients.

Storage Conditions and Stability

Kalydeco must be stored at controlled room temperature, specifically between 20 C to 25 C (68 F to 77 F). The product must be protected from excess heat, moisture, and sunlight. Tablets and granules must remain in their original, tightly closed container.

For oral granules, each packet is for single use only. Once mixed with food or liquid, the suspension is only stable for one hour and must be entirely consumed within this timeframe; the mixture cannot be stored for later use. Food or liquid used for mixing should be at or below room temperature.

Disposal and Safety

Official regulatory instructions require the medication to be stored out of the sight and reach of children. Unused or expired Kalydeco should be discarded using established drug take-back programs or authorized collectors. Disposal via wastewater or household trash is generally discouraged to minimize environmental release.